πŸ‡ΊπŸ‡Έ FDA
Patent

US 12115165

Use of reboxetine to treat narcolepsy

granted A61KA61K31/5375A61P

Quick answer

US patent 12115165 (Use of reboxetine to treat narcolepsy) held by AXSOME THERAPEUTICS, INC. expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AXSOME THERAPEUTICS, INC.
Grant date
Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/5375, A61P, A61P25/02, A61P25/20